Kadimastem develops industrial regenerative medicine therapies based on differentiated cells derived from human embryonic stem cells to treat diseases such as amyotrophic lateral sclerosis (ALS) and diabetes. The technology has been developed as a platform enabling the manufacture of islet-like endocrine cells and glia-restricted progenitors. It has potential applications for diabetes and neurodegenerative diseases such as ALS. The therapy is scalable, industrialized, and will be commercialized as a stable off-the-shelf product to reduce the cost of treatments. For its technology, Kadimastem uses pluripotent cells that can multiply infinitely without losing their naive state or ability to become any cell type. The product is produced under GMP guidelines (similar to traditional therapeutics) in order to reach optimal medical results. The company's process differentiates the cells in the lab, before their injection into the patient. The company's process markedly enhances the efficiency of the treatment.